CytoDyn Files Routine 8-K; No New Material Events Reported
Ticker: CYDY · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1175680
| Field | Detail |
|---|---|
| Company | Cytodyn Inc. (CYDY) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $400,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, no-news, corporate-info
TL;DR
**CytoDyn's 8-K is a non-event, just administrative info.**
AI Summary
CytoDyn Inc. filed an 8-K on January 29, 2024, reporting no new material events. The filing simply re-states the company's basic information, such as its address at 1111 Main Street, Suite 660, Vancouver, Washington, and its telephone number (360) 980-8524. This filing is a routine administrative update and does not contain any new financial or operational news, meaning there's no immediate impact for investors to consider regarding their stock.
Why It Matters
This filing is purely administrative and indicates no significant changes in CytoDyn's operations, leadership, or financial status, so investors should not expect any immediate stock price movement based on this document.
Risk Assessment
Risk Level: low — The filing contains no new information that would introduce or mitigate risk for investors.
Analyst Insight
Smart investors would recognize this as a non-event and not make any trading decisions based solely on this administrative filing. It's a good reminder to check for actual content within 8-K filings, not just the listed item categories.
Key Players & Entities
- CytoDyn Inc. (company) — the registrant filing the 8-K
- Vancouver, Washington (location) — the city and state of CytoDyn's principal executive offices
- January 23, 2024 (date) — the date of the earliest event reported in the 8-K
- January 29, 2024 (date) — the filing date of the 8-K
FAQ
What is the purpose of this specific 8-K filing by CytoDyn Inc.?
This 8-K filing by CytoDyn Inc. is a routine administrative update, primarily re-stating company identification details and confirming no new material events under Items 1.01, 5.02, 7.01, or 9.01 as of the earliest event reported date of January 23, 2024.
What is CytoDyn Inc.'s business address as stated in the filing?
According to the filing, CytoDyn Inc.'s business address is 1111 Main Street, Suite 660, Vancouver, Washington 98660.
What is the telephone number for CytoDyn Inc. provided in the 8-K?
The registrant's telephone number, including area code, is (360) 980-8524.
Does this 8-K report any changes in directors or officers, or new compensatory arrangements?
No, despite listing 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' under Item Information, the body of the filing does not report any such changes or arrangements, indicating no new material events occurred as of January 23, 2024.
Is CytoDyn Inc. an emerging growth company according to this filing?
The filing includes a checkbox to 'Indicate by check mark whether the registrant is an emerging growth company,' but the box is not checked, and the document does not explicitly state whether CytoDyn Inc. is or is not an emerging growth company.
Filing Stats: 1,145 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2024-01-29 08:40:14
Key Financial Figures
- $400,000 — owing: an initial annual base salary of $400,000, subject to periodic adjustment; eligib
Filing Documents
- cydy-20240123x8k.htm (8-K) — 39KB
- cydy-20240123xex10d1.htm (EX-10.1) — 73KB
- cydy-20240123xex99d1.htm (EX-99.1) — 15KB
- cydy-20240123xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-000603.txt ( ) — 353KB
- cydy-20240123.xsd (EX-101.SCH) — 3KB
- cydy-20240123_lab.xml (EX-101.LAB) — 1KB
- cydy-20240123_pre.xml (EX-101.PRE) — 9KB
- cydy-20240123x8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. A copy of the press release issued by the Company on January 29, 2024, and referred to in Item 5.02 of this report is furnished as Exhibit 99.1.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Employment Agreement between the Company and Jacob P. Lalezari, M.D., dated January 26, 2024 99.1 Press release dated January 29, 2024** 104 Cover Page Interactive Data File (formatted as inline XBRL) ** Furnished, not filed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYTODYN INC. Date: January 29, 2024 By /s/ Tyler Blok Tyler Blok Executive Vice President, Legal Affairs